Glenmark has received approval from the Subject Expert Committee (SEC) under CDSCO to conduct a clinical study for relapsed and refractory Multiple Myeloma. This type of cancer involves abnormal plasma cell proliferation in the bone marrow. Understanding and targeting the disease is crucial, and key antigens like CD38 and BCMA are highly expressed on myeloma cells. CD38 is a glycoprotein involved in cell adhesion and signaling, while BCMA belongs to the tumor necrosis factor receptor superfamily.
CD3, found on T cells, is essential for their function and plays a role in signal transduction during T cell activation in response to antigens on infected or cancerous cells. Therapies such as ISB-2001 leverage these antigens for targeted treatment, aiming to harness T cells’ cancer-killing abilities. ISB-2001, a groundbreaking triple-target antibody, simultaneously engages CD38, BCMA, and CD3 proteins to address multiple myeloma. CD38 and BCMA are prevalent on myeloma cells, while CD3 is on cancer-killing T cells. This approach redirects immune cells with heightened specificity, triggering a potent assault on CD38- and/or BCMA-positive myeloma cells. Lab tests show its superior efficacy compared to other bispecific antibodies, even outperforming the combination of Darzalex and teclistamab.
ISB-2001 has secured orphan drug status in the U.S., providing development advantages and potentially revolutionizing multiple myeloma treatment.